Darunavir Viatris

国家: 新西兰

语言: 英文

来源: Medsafe (Medicines Safety Authority)

现在购买

资料单张 资料单张 (PIL)
21-11-2023
产品特点 产品特点 (SPC)
21-11-2023

有效成分:

Darunavir 600mg; Darunavir 600mg

可用日期:

Viatris Limited

INN(国际名称):

Darunavir 600 mg

剂量:

600 mg

药物剂型:

Film coated tablet

组成:

Active: Darunavir 600mg Excipient: Colloidal silicon dioxide Crospovidone Hypromellose Magnesium stearate Microcrystalline cellulose Opadry Orange 85F93050 Sodium starch glycolate Active: Darunavir 600mg Excipient: Colloidal silicon dioxide Crospovidone Hypromellose Magnesium stearate Microcrystalline cellulose Opadry white 85F18422 Purified water   Sodium starch glycolate

处方类型:

Prescription

厂商:

Mylan Laboratories Limited

疗效迹象:

Darunavir Viatris (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients. Darunavir Viatris (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in treatment-experienced paediatric patients aged greater than or equal to 6 years old and weighing at least 40 kg.

產品總結:

Package - Contents - Shelf Life: Bottle, HDPE 150cc, Closure: White PP screw CRC cap with induction sealing liner - 60 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, HDPE 200cc, Closure: Blue PP screw cap with induction sealing liner - 100 tablets - 24 months from date of manufacture stored at or below 25°C

授权日期:

2016-01-06

资料单张

                                Page 1 of 6
NEW ZEALAND CONSUMER MEDICINE INFORMATION
DARUNAVIR VIATRIS
_DARUNAVIR FILM COATED TABLET 400 & 600 MG_
WHAT IS IN THIS LEAFLET
Please read this leaflet carefully
before you start taking Darunavir
Viatris.
This leaflet answers some common
questions about Darunavir Viatris.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Darunavir
Viatris against the benefits they
expect it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE
MEDICINE. You may need to read it
again.
WHAT DARUNAVIR
VIATRIS IS USED FOR
Darunavir Viatris is used to treat
•
Human immunodeficiency virus-
1 (HIV-1) infection in adult
patients.
•
Human immunodeficiency virus
(HIV) infection in treatment-
experienced paediatric patients
aged ≥ 6 years old and weighing
at least 40 kg.
Darunavir Viatris must be taken in
combination with a low dose
ritonavir, and with other anti-HIV
medicines.
Darunavir Viatris contains the active
ingredient darunavir_._ It belongs to a
group of medicines called protease
inhibitors.
It works by reducing the amount of
HIV in your body. Reducing the
amount of HIV in your blood
improves your immune system, and
reduces the risk of developing
illness as a result of HIV infection.
Your doctor may have prescribed
this medicine for another reason.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY THIS
MEDICINE HAS BEEN PRESCRIBED FOR
YOU.
This medicine is available only with
a doctor’s prescription.
BEFORE YOU TAKE
DARUNAVIR VIATRIS
_WHEN YOU MUST NOT TAKE _
_IT_
DO NOT TAKE DARUNAVIR VIATRIS IF
YOU HAVE AN ALLERGY TO:
•
any medicine containing
darunavir.
•
any of the ingredients listed
at the end of this leaflet.
•
Some of the symptoms of
an allergic reaction may
include: shortness of
breath; wheezing or
difficulty breathing; swelling
of the face, lips, tongue or
other part
                                
                                阅读完整的文件
                                
                            

产品特点

                                Page 1 of 52
NEW ZEALAND DATA SHEET
DARUNAVIR VIATRIS
1. PRODUCT NAME
Darunavir Viatris, 300 mg, 400 mg & 600 mg, film coated tablets.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film coated tablet contains 300 mg, 400 mg or 600 mg of
darunavir.
Excipients with known effect: Sodium starch glycolate
Allergen Declaration: Contains phenylalanine
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Darunavir Viatris 300 mg – White to Off white, oval shaped, biconvex
film coated tablets debossed
with 'M' on one side of the tablet and 'DV3' on other side.
Dimensions: (16.50 x 8.20) + 0.3 mm approximately.
Darunavir Viatris 400 mg – White to Off white, oval shaped, biconvex
film coated tablets debossed
with 'M' on one side of the tablet and 'DV4' on other side.
Dimensions: (19.15 x 9.60) + 0.3 mm approximately.
Darunavir Viatris 600 mg – White to Off white, oval shaped, biconvex
film coated tablets debossed
with 'M' on one side of the tablet and 'DV5' on other side.
Dimensions: (21.20 x 10.60) + 0.3 mm approximately.
4. CLINICAL PARTICULARS
_4.1 _
_THERAPEUTIC INDICATIONS_
_ADULT PATIENTS_
Darunavir Viatris (with low dose ritonavir as a pharmacokinetic
enhancer) is indicated in combination
with other antiretroviral agents for the treatment of human
immunodeficiency virus-1 (HIV-1) infection
in adult patients.
_PAEDIATRIC PATIENTS_
Darunavir Viatris (with low dose ritonavir as a pharmacokinetic
enhancer) is indicated in combination
with other antiretroviral agents for the treatment of human
immunodeficiency virus (HIV) infection in
treatment-experienced paediatric patients aged ≥ 6 years old and
weighing at least 40 kg.
Page 2 of 52
_4.2_
_DOSE AND METHOD OF ADMINISTRATION_
DOSE
_ANTIRETROVIRAL TREATMENT-NAÏVE PATIENTS_
The recommended dosage of darunavir is 800 mg once daily (q.d.) taken
with ritonavir 100 mg q.d.
and with food.
_ANTIRETROVIRAL TREATMENT-EXPERIENCED PATIENTS_
For antiretroviral treatment experienced patients, genotypic testing
is recommended. However, when
genotypic tes
                                
                                阅读完整的文件